Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 651 - 675 of 11606 in total
Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent...
Approved
Investigational
Matched Description: … Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown …
All drug products containing encainide hydrochloride. Encainide hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack. The manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991.
Approved
Investigational
Withdrawn
Matched Description: … associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a
Velaglucerase alfa is a gene-activated human recombinant glucocerebrosidase used for the treatment of Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase. Additionally, Velaglucerase alfa has also been investigated for use in Type 3 Gaucher disease.
Approved
Investigational
Matched Description: … Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase. ... Velaglucerase alfa is a gene-activated human recombinant glucocerebrosidase used for the treatment of …
Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized by the deficiency of alpha-galactosidase A.[A259352,L46342] Unlike other forms of recombinant alpha-galactosidase A, such as agalsidase alfa and agalsidase beta, pegunigalsidase alfa uses a...
Approved
Investigational
Matched Description: … Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term ... a different glycosylation pattern. ... the deficiency of alpha-galactosidase A. …
A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.
Approved
Vet approved
Matched Description: … A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. …
Dichlorobenzyl alcohol is a mild antiseptic with a broad spectrum for bacterial and virus associated with mouth and throat infections. Dichlorobenzyl alcohol is considered as an active ingredient found in several marketed OTC products by Health Canada which has categorized this agent as an anatomical therapeutic chemical. On the other...
Approved
Matched Description: … Dichlorobenzyl alcohol is a mild antiseptic with a broad spectrum for bacterial and virus associated …
Oteracil is an adjunct to antineoplastic therapy, used to reduce the toxic side effects associated with chemotherapy. Approved by the European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with DB09257 and DB09256 within the commercially available product "Teysuno". The main active ingredient in Teysuno is DB09256,...
Approved
Matched Description: … The main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic ... By mimicking a class of compounds called "pyrimidines" that are essential components of RNA and DNA, …
Remoxipride is an atypical antipsychotic agent that is specific for dopamine D2 receptors. It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]
Approved
Withdrawn
Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It was later withdrawn...
Approved
Investigational
Withdrawn
Matched Description: … Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ... ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. ... It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy …
A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.
Approved
Investigational
Withdrawn
Matched Description: … A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. …
Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the...
Approved
Matched Description: … build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening ... Insulin aspart is a recombinant, biosynthetic, fast-acting insulin analogue. ... Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type …
Abaloparatide is an N-terminal analog of parathyroid hormone-related protein (PTHrP) and an agonist at the parathyroid hormone type 1 (PTH1) receptor. It is a synthetic 34 amino acid peptide with 41% homology to human parathyroid hormone 1-34 and human PTHrP 1-34. Abaloparatide and PTHrP share the first 21 amino acids...
Approved
Investigational
Matched Description: … [L740] It is a synthetic 34 amino acid peptide with 41% homology to human parathyroid hormone 1-34 and …
High levels of LDL cholesterol (LDL-C) are a major risk factor for cardiovascular events. Caused by genetic mutations or lifestyle factors, hypercholesterolemia can significantly reduce quality of life and increase the risk of mortality from cardiovascular disease. About 1 in 4 patients, or 15 million Americans with elevated LDL-C, are...
Approved
Investigational
Matched Description: … High levels of LDL cholesterol (LDL-C) are a major risk factor for cardiovascular events. ... Bempedoic acid is first-in-class adenosine triphosphate-citrate lyase (ACL) inhibitor used once a ... A combination product of bempedoic acid and [ezetimibe] was approved on February 26, 2020 for increased …
Clodronic acid is a first generation bisphosphonate similar to etidronic acid and tiludronic acid. These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification. clodronate’s use has decreased over the years in favor of the third generation, nitrogen containing bisphosphonate zoledronic acid, ibandronic acid,...
Approved
Investigational
Vet approved
Matched Description: … Clodronic acid is a first generation bisphosphonate similar to [etidronic acid] and [tiludronic acid] ... [A203111] These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification …
A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.
Approved
Matched Description: … A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties …
A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop...
Approved
Investigational
Matched Description: … This compound has been classified as a loop or high ceiling diuretic. ... A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of …
Bifonazole is an azole antifungal drug.
Approved
Investigational
Halazepam is a benzodiazepine derivative drug exerting anxiolytic, anticonvulsant, sedative, a muscle relaxing effects.[A1212, A178114] It has been shown to be less toxic than chlordiazepoxide or diazepam. This drug is no longer marketed in the United States, and was withdrawn by Schering, its manufacturer, in 2009.[L6226, L6229]
Approved
Illicit
Withdrawn
Matched Description: … Halazepam is a _benzodiazepine_ derivative drug exerting anxiolytic, anticonvulsant, sedative, a muscle …
Quinethazone, marketed as Hydromox, is a thiazide diuretic indicated for hypertension. Patients may experience adverse reactions such as dizziness, dry mouth, nausea, and hypokalemia.
Approved
Matched Description: … Quinethazone, marketed as Hydromox, is a thiazide diuretic indicated for hypertension. …
A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection from influenza viruses. These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in...
Approved
Matched Description: … A seasonally-specific component of the influenza vaccine. ... The influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection ... Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed …
Celiprolol is indicated for the management of mild to moderate hypertension and effort-induced angina pectoris. It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 receptor antagonist. In 2010 a clinical trial has suggested a use for this medication in the prevention of...
Approved
Investigational
Matched Description: … It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 ... In 2010 a clinical trial has suggested a use for this medication in the prevention of vascular complications ... of a rare inherited disease called vascular Ehlers–Danlos syndrome. …
Ledipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most...
Approved
Matched Description: … Ledipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat ... HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 ... It is effective against genotypes 1a, 1b, 4a, and 5a and with a lesser activity against genotypes 2a …
Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal. Tafamidis was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 May 2019.
Approved
Investigational
Cipaglucosidase alfa (ATB200) is a novel recombinant human acid alpha-glucosidase (GAA) investigated for the treatment of patients with Pompe disease, a rare inherited metabolic disorder characterized by a deficiency in GAA. Other types of enzyme replacement therapy for the treatment of Pompe disease include alglucosidase alfa and avalglucosidase alfa. Cipaglucosidase...
Approved
Investigational
Matched Description: … a deficiency in GAA. ... Compared to alglucosidase alfa, cipaglucosidase alfa has a higher M6P content. ... Cipaglucosidase alfa (ATB200) is a novel recombinant human acid alpha-glucosidase (GAA) investigated …
Displaying drugs 651 - 675 of 11606 in total